MIROMATRIX MEDICAL INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • July 1st, 2022 • Miromatrix Medical Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJuly 1st, 2022 Company Industry JurisdictionAs further set forth in this agreement (this “Agreement”), Miromatrix Medical Inc., a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from time to time through Piper Sandler & Co. (the “Agent”), as sales agent, the Company’s common stock, par value $0.00001 per share (the “Common Stock”) (such shares of Common Stock to be sold pursuant to this Agreement, the “Shares”) on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of shares of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agent shall have no obligation in connection with such compliance.
EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • September 4th, 2020 • Aravive, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 4th, 2020 Company Industry JurisdictionAs further set forth in this agreement (this “Agreement”), Aravive, Inc., a Delaware corporation (the “Company”), proposes to issue and sell from time to time through Piper Sandler & Co. and Cantor Fitzgerald & Co. (each an “Agent”, and together, the “Agents”), as sales agents, the Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”) (such Common Stock to be sold pursuant to this Agreement, the “Shares”), on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agents shall have no obligation in connection with such compliance.
APTOSE BIOSCIENCES INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • May 5th, 2020 • Aptose Biosciences Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMay 5th, 2020 Company Industry JurisdictionAs further set forth in this agreement (this “Agreement”), Aptose Biosciences Inc., a company incorporated under the Canada Business Corporations Act (the “Company”), proposes to issue and sell from time to time through Piper Sandler & Co. and Canaccord Genuity LLC (each an “Agent”, and together, the “Agents”), as sales agents, the Company’s common shares, no par value per share (the “Common Shares”) (such Common Shares to be sold pursuant to this Agreement, the “Shares”) on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agents shall have no obligation in connection with such compliance.
GEMPHIRE THERAPEUTICS INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • September 1st, 2017 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 1st, 2017 Company Industry JurisdictionAs further set forth in this agreement (this “Agreement”), Gemphire Therapeutics Inc., a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from time to time through Piper Jaffray & Co. (the “Agent”), as sales agent, the Company’s common stock, par value $0.001 per share (the “Common Stock”) (such shares of Common Stock to be sold pursuant to this Agreement, the “Shares”) on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agent shall have no obligation in connection with such compliance.